Lindagan, Sayba M.

HRN: 07-62-08  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/28/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/28/2025
11/05/2025
IV
2.25g
Q8h
Complicated UTI
Checking Final Appropriateness 

Indication:  Empiric Then Culture-directed    Type of Infection:  Urinary Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: